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Abstract
Background: Sorafenib is a multiple receptor tyrosine kinase inhibitor known to prolong overall survival in patients
with advanced hepatocellular carcinoma (HCC). Predicting this drug’s survival benefits is challenging because clinical
responses are rarely measurable during treatment. In this study, we hypothesized that serum cytokines levels could
predict the survival of advanced HCC patients, as sorafenib targets signaling pathways activated in the tumor stromal
microenvironment and potentially affects serum cytokine profiles.
Methods: Of 143 patients with advanced-stage HCC, 104 who were recruited between 2003 and 2007 received hepatic
arterial infusion chemotherapy (HAIC) that mainly targets tumor epithelial cells at S-phase (cohort 1); additionally, 39
recruited between 2010 and 2012 received sorafenib, which primarily targets the stromal vascular endothelial cells. Serum
samples were collected and aliquoted prior to the treatment. Serum EGF, bFGF, HGF, IFN-γ, IL-10, IL-12, IL-2, IL-4, IL-5, IL-6,
IL-8, IP-10, MIG, PDGF-BB, SCF, SDF1, TGF-β, TGF-α, TNF-α, and VEGF-A were measured via enzyme-linked immunosorbent
assays. The Modified Response Evaluation Criteria in Solid Tumors were used to assess tumor responses.
Results: The median survival time of HCC patients in cohorts 1 (HAIC-treated) and 2 (sorafenib-treated) were 12.0 and 12.
4 months, respectively. Kaplan-Meier analysis revealed no significant survival differences between the 2 groups. Patients
who survived more than 2 years after sorafenib treatment exhibited higher serum levels of IL-10, IL-12, TNF-a, IL-8, SDF-1,
EGF, PDGF-BB, SCF, and TGF-α. Furthermore, cohort 2 patients with higher serum IL-5 (>12 pg/mL), IL-8 (>10 pg/mL),
PDGF-BB (>300 pg/mL), and VEGF-A (>50 pg/mL) levels achieved longer survival; cohort 1 patients did not. Hierarchical
cluster analysis of 6 cytokines robustly enriched for comparison analysis between cohorts 1 and 2 (IL-5, IL-8, TGF-α, PDGF-
BB, CXCL9, and VEGF-A) revealed that elevation of these cytokines correlated with better survival when treated with
sorafenib but not with HAIC.
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Conclusions: Patients who exhibited survival benefits owing to sorafenib treatment tended to present higher serum
cytokines levels, potentially reflecting the activation of stromal signaling in the tumor microenvironment. Our study thus
introduces novel biomarkers that may identify advanced HCC patients who may experience survival benefits with
sorafenib treatment.
Keywords: Hepatocellular carcinoma, Sorafenib, Hepatic arterial infusion chemotherapy, Cytokine, Chemokine, Growth
factor
Background
Hepatocellular carcinoma (HCC) is the fifth most
common cancer and the second leading cause of
cancer death in men worldwide [1]. Sorafenib tosylate
is a multikinase inhibitor that has been reported to
prolong overall survival (by a median of approxi-
mately 3 months) in patients with advanced HCC;
however, its response rate is generally <5% according
to the Response Evaluation Criteria in Solid Tumors
[2, 3]. In contrast, hepatic arterial infusion chemo-
therapy (HAIC) using 5-fluorouracil and cisplatin is
widely used for the treatment of advanced HCC in
Japan, to which the patient response rates are gener-
ally 20–30%. Nevertheless, HAIC does not signifi-
cantly improve overall survival compared to sorafenib.
The responses of the patients who receive HAIC for
treating HCC reportedly predict their overall survival,
although it is challenging to make similar predictions
prior to the treatment. Thus, novel biomarkers that
can predict the outcomes of patients with advanced
HCC with respect to current treatment modalities are
required [4]. However, no studies thus far have success-
fully identified useful biomarkers that can predict the clin-
ical responses or overall survival rates in patients who
received sorafenib or HAIC for advanced HCC.
Recent evidence suggests that the tumor microenviron-
ment plays a pivotal role in the response to anti-cancer
agents and molecular targeted therapies [5–7]. Because
sorafenib targets the vascular endothelial growth factor
(VEGF) receptor 2 (VEGFR2) expressed in endothelial
cells, activation of VEGF signaling may correlate with tu-
mors’ responses to sorafenib treatment. Indeed, a recent
study indicated that HCC with VEGFA amplification
showed better responses to sorafenib [8]. Furthermore, a
study evaluating genome alteration in advanced HCC pa-
tients who responded to sorafenib found that FGF3/4,
which may result in the activation of fibroblast growth fac-
tor (FGF) signaling in the HCC microenvironment, was
amplified [9]. The role of serum cytokines as biomarkers
for the prediction of sorafenib responses is intriguing [10];
however, it remains unclear if such cytokines are sensitive
enough to reflect the status of the tumor microenviron-
ment, which in turn might affect the clinical response in
advanced HCCs. In this study, we investigated 20 serum
cytokines and growth factors in patients with advanced-
stage HCC; their expression profiles were compared be-
tween 2 HCC cohorts of patients who received HAIC and
sorafenib, respectively. This was particularly important
since the former mainly targets S-phase tumor epithelial




There were 143 patients with advanced HCC enrolled
in our institute (Kanazawa University); 65 with
Barcelona Clinic Liver Cancer stage B, 72 with stage
C, and 6 with stage D. All patients had Eastern
Cooperative Oncology Group performance status
scores of 0/1/2 (Table 1). Among these patients, 104
who were recruited between 2003 and 2007 received
interferon and HAIC using 5-fluorouracil (300 mg/
m2, days 1–5 and 8–12) alone or in combination with
cisplatin (20 mg/m2, days 1 and 8), according to the
inclusion and assignment criteria of our previous
study [11]. Because sorafenib was approved for the
treatment of advanced HCC in 2009, 39 patients
recruited in the years 2010–2012 underwent sorafenib
treatment (400 mg twice daily). The ‘Response
Evaluation Criteria in Solid Tumors’ rules were used
to assess tumor responses according to dynamic com-
puted tomography findings. Sera from all patients
were aliquoted and stored at −20 °C prior to treat-
ment. This study was approved by the Institutional
Review Board of the Kanazawa University [The ethical
approval reference number: 2015–257 (2142)], and all
patients provided written informed consent for inclu-
sion in the study.
Serum profiles
A total of 20 cytokines, including serum epidermal
growth factor (EGF), basic FGF (bFGF), hepatocyte
growth factor (HGF), interferon (IFN)-γ, interleukin
(IL)-10, IL-12, IL-2, IL-4, IL-5, IL-6, IL-8, chemokine (C-
X-C motif ) ligand (CXCL)-9, CXCL10, platelet-derived
growth factor (PDGF)-BB, stem cell factor (SCF), stro-
mal cell-derived factor 1 (SDF1), transforming growth
factor (TGF)-α, transforming growth factor (TGF)-β,
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tumor necrosis factor (TNF)-α, and vascular endothelial
growth factor (VEGF-A), were measured in duplicate by
a multiplex biometric enzyme-linked immunosorbent assay
(ELISA)-based immunoassay (Bio-Plex, Bio-Rad Laborator-
ies, Inc. Hercules, CA) according to the manufacturer’s
protocol. Serum alpha-fetoprotein (AFP), lectin-reactive
AFP (AFP-L3), and des-gamma carboxyprothrombin
(DCP) were measured by conventional methods using
commercially available assays at the Kanazawa University
Hospital.
Statistical analysis
Student t tests or χ2-tests were performed using the
GraphPad Prism software version 5.0.4 (GraphPad Soft-
ware) to compare the 2 groups. Kaplan-Meier survival
analyses with log-rank tests were also performed using the
GraphPad Prism software. Hierarchical clustering analysis
was performed using the Genesis software (v. 1.6.0 beta).
Results
Baseline cohort characteristics
A total of 143 advanced-stage HCC patients were included
in this study. Patients who received HAIC were recruited
between 2003 and 2007 (cohort 1), whereas those who re-
ceived sorafenib were recruited between 2010 and 2012
(cohort 2); sorafenib was only introduced in Japan in
2009. The profiles of the patients in both cohorts are
shown in Table 1. The patients in both cohorts were simi-
lar with respect to age and sex, as well as to AFP, AFP-L3,
and DCP levels. However, the number of patients with
Child-Pugh classes B and C in cohort 1 were significantly
higher than those in cohort 2 (P = 0.042). This might be
related to the inclusion of 4 decompensated Child-Pugh C
cirrhosis patients with advanced HCCs, because HAIC
was successfully used in such patients [11]. The frequency
of vascular invasion was higher in cohort 1 (P = 0.04),
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Fig. 1 Characteristics of hepatocellular carcinoma (HCC) patients in
the 2 cohorts. a Kaplan-Meier survival analysis of HCC patients in the
2 cohorts. The median survival time of HCC patients who received
hepatic arterial infusion chemotherapy (HAIC) and sorafenib was
12.0 months and 12.4 months, respectively. There were no significant
survival differences between the two cohorts (log-rank test, P= 0.65). b
Serum levels of 6 cytokines (IL-5, IL-8, CXCL9, PDGF-BB, TGF-α, and VEGF-
A) were distributed similarly in the sera of HCC patients in cohorts 1 and 2






Age (y), median, range 65.0 (40–82) 67.0 (37–83) 0.306
Gender(Male: Female) 86:18 32:7 0.928
Child-Pugh score 6.5 5.9 0.028
Child-Pugh A 60 31 0.042
Child-Pugh B 40 8
Child-Pugh C 4 0
Performance status (0/1/2) 91/11/2 37/1/1 0.301
Prior treatment (surgical
resection)
5.2% (20) 33.3% (13) 0.075
Prior treatment
(radiofrequency ablation)
51.0% (53) 53.8% (21) 0.759
Prior treatment (TACE/TAE) 51.9% (54) 76.9% (30) 0.007
Size of dominant tumour
(mm)
32.3 ± 21.2 42.0 ± 27.9 0.066
Multiple tumour 69.2% (72) 71.8% (28) 0.766
AFP (ng/ml) mean ± SE 13,110.5 ±
5278.7
3438.7 ± 1123.3 0.259
AFP-L3 (%) ± SE 28.6 ± 2.7 38.8 ± 5.4 0.073
DCP (mAU/ml) ± SE 21,194.0 ±
6814.7
5418.4 ± 2896.5 0.161
Vascular invasion (%) 35.6% (37) 17.9% (7) 0.042
Distant metastasis (%) 10.6% (11) 35.9% (14) <0.001
BCLC stage (B/C/D) 47/51/6 18/21/0 0.303
Tumor responses by mRECIST
(CR / PR)
34.6% (36) 2.6% (1) <0.001
AFP alpha-fetoprotein, AFP-L3 lectin-reactive AFP, BCLC Barcelona-Clínic Liver
Cancer, CR complete response, DCP des-gamma carboxyprothrombin, HAIC
hepatic arterial infusion chemotherapy, PR partial response, SD standard devi-
ation, SE standard error, TACE/TAE transcatheter arterial chemoembolization/
transcatheter arterial embolization)
aχ2 tests
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Clinical responses (complete or partial remission) were
observed in 36/104 cases (34.6%) in cohort 1 and 1/39
cases (2.6%) in cohort 2; such outcomes are consistent
with previously reported results [2, 3, 11]. Although the
baseline characteristics of the 2 cohorts showed some
differences, the median survival times of patients who
received HAIC and sorafenib were 12.0 months and
12.4 months, respectively. Kaplan-Meier survival analysis
revealed no significant survival differences between the 2
cohorts (log-rank test, P = 0.65) (Fig. 1a).
Next, we evaluated the expression levels of 20 cyto-
kines using patients’ sera obtained prior to treatment in
both cohorts. Because we evaluated the serum profiles of
patients in cohort 1 in 2009 and cohort 2 in 2013, we
had used different versions of the Bio-Plex assay kits for
the analyses; therefore, we first compared the distribu-
tion of serum proteins measured in cohorts 1 and 2. Un-
expectedly, the distribution of 14 cytokines (EGF, bFGF,
HGF, IFN-γ, IL-10, IL-12, IL-2, IL-4, IL-6, CXCL10, SCF,
SDF1, TGF-β, and TNF-α) differed between cohorts 1
and 2, suggesting that the improvement of the detection
threshold of the Bio-Plex analysis system might bias the
analysis. We therefore excluded these 14 cytokines from
comparison analysis of the serum profiles between
cohort 1 and 2. The remaining 6 cytokines (IL-5, IL-8,
CXCL9, PDGF-BB, TGF-α, and VEGF-A) showed no
difference in terms of distribution in cohorts 1 and 2
(Fig. 1b). We thus analyzed these cytokines to evaluate
their survival-related significance in cohorts 1 and 2.
Treatment response and serum cytokines
We compared the patients’ serum profiles in cohort 1
based on the clinical responses (complete response/partial
response and stable disease/progressive disease) (Table 2).
Patients with clinical responses had higher serum SDF1
levels (P = 0.02) and lower serum HGF (P = 0.04) and IL-4
(P = 0.04) levels compared to non-responders. We then
classified the HCCs as HGF-high and -low, IL-4-high and
-low, and SDF1-high and -low using the median values of
non-responders as cutoff values: HGF (500 pg/mL), IL-4
(1 pg/mL), and SDF1 (1 pg/mL). Kaplan-Meier based on
the median indicated that patients with high serum IL-4
levels showed significantly poorer prognoses (P = 0.03)
(Additional file 1: Figure S1).
Similarly, we evaluated the serum cytokine levels in HCC
patients who received sorafenib treatment. Because such
treatment rarely showed clinical responses, we classified
Table 3 Baseline serum cytokines in Cohort 2 (sorafenib-treated
patients)
Cytokines
(pg/mL, mean ± SE)
Survival time
≥ 2 years(n = 7)
Survival time
< 2 years(n = 32)
P-valuea
EGF 213.7 ± 99.5 58.3 ± 10.6 0.004
FGF 89.6 ± 46.8 103.4 ± 19.4 0.770
HGF 483.4 ± 111.9 313.0 ± 45.8 0.133
IFN-γ 23.2 ± 4.2 16.0 ± 1.8 0.103
IL-10 32.1 ± 10.6 16.2 ± 1.7 0.012
IL-12 (p70) 23.0 ± 4.3 14.6 ± 1.6 0.039
IL-2 50.8 ± 12.0 34.1 ± 3.7 0.093
IL-4 18.9 ± 3.5 13.2 ± 1.5 0.132
IL-5 20.3 ± 4.8 14.4 ± 2.1 0.246
IL-6 25.2 ± 7.5 18.2 ± 2.4 0.270
IL-8/CXCL8 80.1 ± 36.3 37.1 ± 5.5 0.039
CXCL10 1078.6 ± 339.9 631.9 ± 116.2 0.136
CXCL9 345.3 ± 65.8 241.8 ± 32.1 0.178
PDGF-BB 620.6 ± 250.4 171.0 ± 31.6 0.001
SCF 78.9 ± 12.8 48.0 ± 5.3 0.021
SDF-1 876.0 ± 148.1 549.1 ± 54.1 0.020
TGF-β 32.4 ± 6.4 23.2 ± 2.5 0.143
TGF-α 31.6 ± 11.5 16.2 ± 1.8 0.020
TNF-α 22.9 ± 8.0 13.0 ± 1.4 0.042
VEGF-A 94.6 ± 10.2 86.7 ± 17.9 0.841
SE standard error
aUnpaired t-tests
Table 2 Baseline serum cytokines in Cohort 1 (hepatic arterial
infusion chemotherapy-treated patients)
Cytokines (pg/mL, mean ± SE) CR/PR group SD/PD group P-valuea
EGF 20.8 ± 3.8 21.6 ± 3.0 0.882
FGF 2.84 ± 1.63 8.40 ± 2.53 0.134
HGF 523.9 ± 50.3 739.8 ± 71.6 0.043
IFN-γ 0.109 ± 0.064 1.343 ± 0.699 0.203
IL-10 0.813 ± 0.169 1.239 ± 0.219 0.193
IL-12 (p70) 8.41 ± 1.17 10.77 ± 1.05 0.164
IL-2 0.297 ± 0.092 1.118 ± 0.568 0.299
IL-4 0.586 ± 0.170 1.213 ± 0.197 0.038
IL-5 17.3 ± 5.5 15.6 ± 2.0 0.718
IL-6 10.90 ± 3.94 9.05 ± 1.65 0.614
IL-8/CXCL8 61.3 ± 37.1 18.7 ± 2.7 0.119
CXCL10 358.3 ± 41.1 359.1 ± 30.3 0.988
CXCL9 176.6 ± 14.0 205.8 ± 30.6 0.502
PDGF-BB 152.5 ± 20.9 193.6 ± 24.3 0.265
SCF 14.1 ± 1.3 16.4 ± 1.0 0.189
SDF-1 60.3 ± 26.3 13.1 ± 5.0 0.022
TGF-β 5.17 ± 3.42 1.64 ± 0.71 0.188
TGF-α 34.0 ± 23.8 14.2 ± 6.3 0.307
TNF-α 1.23 ± 0.31 1.87 ± 0.30 0.184
VEGF-A 65.1 ± 9.4 83.6 ± 6.9 0.116
CR complete response, PD progressive disease, PR partial response, SD stable
disease, SE standard error
aUnpaired t-tests
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patients with HCC into long survivors (overall survival
≥2 years) and non-long survivors (overall survival <2 years)
(Table 3). Surprisingly, 9 of 20 cytokines (IL-10, IL-12,
TNF-α, IL-8, SDF-1, EGF, PDGF-BB, SCF, and TGF-α)
were significantly elevated in long survivors compared to
non-long survivors (P < 0.05) (Table 3).
Overall survival and serum cytokines
Because 3 of the 9 cytokines described above (IL-8,
PDGF-BB, and TGF-α) could be used for comparison
analysis between cohorts 1 and 2, we further evaluated
their expression levels in terms of prediction of overall
survival. The remaining 3 cytokines that could be used for
comparison analysis (IL-5, CXCL9, and VEGF-A) showed
no difference between long survivors and non-long survi-
vors in both cohorts (Additional file 2: Figure S2). Inter-
estingly, we found that serum IL-8, PDGF-BB, and TGF-α
were significantly higher in long survivors in cohort 2 (P
< 0.05) (Fig. 2a) but not in cohort 1 (Fig. 2b).
We set the cutoff values of 6 serum cytokines that can
be used for comparison analysis between cohorts 1 and
2 based on their median values in 143 HCC cases as fol-
lows: IL-5 (12 pg/mL), IL-8 (10 pg/mL), CXCL9
(100 pg/mL), PDGF-BB (300 pg/mL), VEGF-A (50 ng/
mL), and TGF-α (20 ng/mL). Kaplan-Meier survival ana-
lysis showed that patients with high serum IL-5, IL-8,
PDGF-BB, and VEGF-A showed significantly better
survival when treated with sorafenib; moreover, high
CXCL9 and TGF-α levels were also associated with bet-
ter survival with borderline significance (Fig. 3a). In con-
trast, serum cytokine levels did not influence survival in
patients who received HAIC when using the same cutoff
values (Fig. 3b).
Next, we incorporated all 6 serum cytokines into a
hierarchical clustering analysis to classify HCCs more
extensively. Patients were classified into two groups
based on the clustering profiles of the serum
cytokine, “cytokines-elevated” and “cytokines-non-ele-
vated”, in both cohorts 1 and 2 (Fig. 4a and b).
Cytokines-elevated patients showed better survival
compared to cytokines-non-elevated patients in cohort
2 (Fig. 4c). In contrast, cytokines-elevated patients
showed similar survival rates compared to cytokines-
non-elevated patients in cohort 1 (Fig. 4d).
Potential survival benefit of “cytokines-non-elevated”
HCC patients when treated with HAIC
Our data suggested that sorafenib is effective in
prolonging the overall survival in patients with
advanced HCC, with activated stromal cell signaling
potentially affecting the serum cytokine profiles.
However, sorafenib appears to have limited effects on
HCCs without such activation in the tumor micro-
























































































Fig. 2 Comparison of serum cytokine levels between long survivors and non-long survivors in the 2 cohorts. a In cohort 2 (sorafenib-treated
patients), serum IL-8, PDGF-BB, and TGF-α levels were higher in long survivors (overall survival ≥2 years). b In cohort 1 (hepatic arterial infusion
chemotherapy-treated patients), there were no differences in these serum cytokine levels between long and non-long survivors
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rates as related to the 6 serum cytokines in patients
who received sorafenib and HAIC to evaluate the ef-
fects of HAIC on HCC absent the activated stromal
cell signaling. In cases of HCCs with low serum
VEGF-A (Fig. 5a) (≤50 pg/mL, represented by 43 of
104 patients treated with HAIC and 10 of 39 treated
with sorafenib), IL-8 (Fig. 5b) (≤10 pg/mL, repre-
sented by 50 of 104 patients treated with HAIC and
6 of 39 treated with sorafenib), and IL-5 (Fig. 5c)
(≤12 pg/mL, represented by 57 of 104 patients
treated with HAIC and 13 of 39 treated with sorafe-
nib), patients with low VEGF-A and IL-8 who
received HAIC exhibited significantly better survival
compared to those treated with sorafenib; those with
low IL-5 also showed better survival with borderline
significance. In cases of low serum TGF-α (≤20 pg/
mL), PDGF-BB (≤300 pg/mL), and CXCL9 (≤100 pg/
mL), HCC patients who received HAIC showed
similar survival rates compared to those treated with
sorafenib (Additional file 3: Figure S3).
Discussion
Taken together, our findings suggested that the se-
lected serum cytokines identified herein may be useful
biomarkers for predicting HCC patients who may
achieve survival benefits owing to sorafenib treatment.
Sorafenib is widely used for the first-line treatment of
advanced HCC patients worldwide. However, it has
been difficult to identify HCC patients who will
achieve survival benefits owing to sorafenib treatment.
Several previous studies demonstrated that genomic
alterations such as VEGFA or FGF3/4 amplification
can identify HCC patients who showed clinical
responses after sorafenib treatment, although tumor
biopsy specimens are required. Herein, we showed for
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Fig. 3 Kaplan-Meier survival analyses of patients with high and low serum cytokines in the 2 cohorts. a Sorafenib-treated patients with high
serum cytokine levels showed better survival with statistical (IL-5, IL-8, PDGF-BB, VEGF-A) or borderline significance (CXCL9 and TGF-α). b Patients
who received hepatic arterial infusion chemotherapy showed similar survival rates regardless of serum cytokine levels
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cytokines may be useful for identifying HCC patients
with potentially active microenvironmental signaling
that may increase sensitivity to sorafenib. Interest-
ingly, the same cytokines were not useful for identify-
ing HCC patients who may benefit from HAIC,
potentially because of the different cell populations
targeted by HAIC (which mainly S-phase tumor
epithelial cells) and sorafenib (which mainly targets
the stromal vascular endothelial cells).
We identified three cytokines (HGF, IL-4, and SDF-1)
that are differentially elevated in clinical responders
compared with non-responders; among them, only
serum IL-4, a Th2 cytokine, could discriminate HCCs
according to overall survival. Because Th2 cytokines may
contribute to worse prognosis in HCC patients who
underwent surgery, it is possible that Th2 cytokines may
somehow influence the tumor responses to cytotoxic
reagents [12]. Further studies are required to evaluate
the role of Th2 cytokines and their effects on HCC
phenotypes in terms of chemoresistance.
We found that serum IL-5, IL-8, CXCL9, PDGF-BB,
TGF-α, and VEGF-A were elevated in the long survivors
group among HCC patients who received sorafenib
compared to those who received HAIC. Because sorafe-
nib is known to target multiple receptor tyrosine kinases
such as PDGF receptors, VEGFRs, and EGF receptors, it
makes sense that elevation of the serum cytokines
PDGF-BB, TGF-α, and VEGF-A could reflect the activa-
tion status of microenvironmental signaling pathways
that may correlate with survival benefits achieved by
sorafenib [13, 14]. However, it was unclear if sorafenib
directly targets the IL-8 receptor CXCR1/2, IL-5 recep-
tor, and CXCL9 receptor CXCR3. It is possible that these
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Fig. 4 Cytokines profiles and hepatocellular carcinoma (HCC) prognosis. a & b Hierarchical clustering analysis of 6 serum cytokines profiles.
Hierarchical clustering classified HCCs into 2 groups (“cytokines-elevated” and “cytokines-non-elevated”) in a comprehensive and non-arbitrary
manner in cohorts 2 (a; sorafenib-treated patients) and 1 (b; hepatic arterial infusion chemotherapy [HAIC]). c & d Cytokines-elevated patients
showed better survival compared to cytokines-non-elevated patients in cohort 2 (c; sorafenib-treated patients) but not in cohort 1 (d;
HAIC-treated patients)
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tyrosine kinases targeted by sorafenib; future studies are
required to test these hypotheses.
We detected differences in vascular invasion and metas-
tasis profiles between cohorts 1 and 2. Although the rea-
sons for these differences were unclear, they may be
attributed to the fact that sorafenib is frequently used to
treat patients with advanced HCC who have distant organ
metastasis, while HAIC mainly targets intrahepatic lesions
and is considered ineffective against metastatic lesions.
This study has some limitations. First, it was
performed at a single institution. Second, the profiles
of the patients in the 2 cohorts were different in
terms of the frequency of vascular invasion and dis-
tant metastasis. Third, the sample size of the patients
who received sorafenib was small; hence, the statis-
tical outcomes of this analysis should be validated in
an independent cohort, which we are currently
recruiting the patients. Fourth, our two HCC cohorts
may have been subject to selection bias, which might
make the treatment outcomes as determined by cyto-
kine evaluation uncertain. Fifth, samples were only
evaluated at a single time point (baseline); serial mea-
surements may be more useful for predicting poten-
tial benefits. Future prospective studies are required to
address these limitations by recruiting more patients in a
multicenter setting using the same protocols.
Conclusion
Patients who exhibited survival benefits by sorafenib or
HAIC showed different pre-treatment cytokine profiles.
Evaluation of the serum cytokines investigated in our
study may be useful to predict responses in advanced
HCC patients who receive sorafenib, which mainly tar-
gets stromal cells such as vascular endothelial cells. Our
data also suggested that cytokines have limited roles in
predicting HCC responses in patients who receive
HAIC, which mainly targets cancer epithelial cells.
Hence, our findings expose important biomarkers in ad-
vanced HCC patients that can predict survival benefits
owing to sorafenib or HAIC prior to the treatment.
Additional files
Additional file 1: Figure S1. Kaplan-Meier survival analysis of HCC
patients classified as HGF-high and -low, IL-4-high and -low, and SDF1-
high and –low in Cohort 2. (PDF 101 kb)
Additional file 2: Figure S2. Comparison of serum IL-5, CXCL9, and
VGEF-A levels between long survivors and non-long survivors in the 2 co-
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Fig. 5 Comparisons of the survival of hepatocellular carcinoma (HCC)
patients with low cytokine levels. a Kaplan-Meier survival of HCC pa-
tients with low serum VEGF-A levels treated with sorafenib or hepatic
arterial infusion chemotherapy (HAIC). b Kaplan-Meier survival curves of
HCC patients with low serum IL-8 levels treated with sorafenib or HAIC.
c Kaplan-Meier survival curves of HCC patients with low serum IL-5
levels treated with sorafenib or HAIC
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